J&J's Alzheimer's research group at Janssen has found positive signs for bapineuzumab, its late-stage Alzheimer's therapeutic vaccine. In a study using mice, researchers found that those who were inoculated performed a simple task more effectively, which could mean the vax was successful at stopping amyloid plaque from binding with neurons. Story